文献速递妇科

咪喹莫特治疗阴道上皮内瘤变2-3级的系统评价与荟萃分析

Imiquimod for vaginal intraepithelial neoplasia 2-3: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2020-10-01

本研究通过系统检索和本院病例分析,评估咪喹莫特治疗阴道上皮内瘤变(VaIN)2-3级的疗效,共纳入5篇文献28例及本院9例患者。汇总完全缓解率(CR)为0.76(95%CI 0.59-0.87),缓解率为0.89(95%CI 0.71-0.97),仅1例需停药。结论认为咪喹莫特可能是VaIN 2-3的有效治疗选择。

要点

  • 咪喹莫特治疗VaIN 2-3的汇总完全缓解率为76%,缓解率为89%。
  • 仅1例患者因不良反应需终止治疗,耐受性较好。
  • 有子宫切除史者完全缓解率0.98,无子宫切除史者0.60,但置信区间重叠。

核心结论

  • 咪喹莫特可能是阴道上皮内瘤变2-3级的有效治疗选择。

主要发现

  • 汇总完全缓解率(CR)为0.76(95%CI 0.59-0.87),汇总缓解率为0.89(95%CI 0.71-0.97)。
  • 仅1例报道病例需要终止治疗。
  • 亚组分析:有子宫切除史者CR率为0.98(95%CI 0.11-1.0),无子宫切除史者为0.60(95%CI 0.30-0.84),率比为0.83(95%CI 0.48-1.19)。
  • 有和无子宫切除史的汇总缓解率未估计,率比为0.83(95%CI 0.54-1.09)。

关键数值与推荐

  • 完全缓解率0.76(95%CI 0.59-0.87),缓解率0.89(95%CI 0.71-0.97)。
  • 有子宫切除史者CR率0.98(95%CI 0.11-1.0),无子宫切除史者0.60(95%CI 0.30-0.84)。
  • 有和无子宫切除史的CR率比为0.83(95%CI 0.48-1.19),缓解率比为0.83(95%CI 0.54-1.09)。

临床怎么用

  • 对于VaIN 2-3患者,咪喹莫特可作为潜在治疗选项,尤其对于有子宫切除史者可能疗效更佳。
  • 治疗过程中需监测不良反应,必要时终止治疗。

局限性

  • 有子宫切除史亚组的置信区间宽,结果不确定性大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The treatment strategy for vaginal intraepithelial neoplasia (VaIN) 2-3 has not been established. This study aimed to investigate the efficacy of imiquimod in VaIN 2-3. METHODS: Electronic databases (PubMed, EMBASE, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials) were searched from their inception until October 2019 and articles reporting imiquimod treatment for VaIN 2-3 were extracted. Additionally, the clinical records of women with VaIN 2-3 who had been treated with imiquimod in Shizuoka General Hospital from January 2016 to May 2020 were investigated. The data from the systematic search and the data from our hospital were analyzed, and a pooled complete response (CR) rate and response rate of imiquimod treatment for VaIN 2-3 were estimated. As a subgroup analysis, the CR rates and response rates were compared between women with and without a history of hysterectomy, and the rate ratio was calculated. RESULTS: Five articles described 28 women with VaIN 2-3 who underwent imiquimod treatment, and nine women with VaIN 2-3 were treated with imiquimod in our hospital. The discontinuation of the treatment was required in only one patient of the reported cases. The pooled CR rate and response rate of imiquimod, regardless of a history of hysterectomy, was 0.76 (95% CI, 0.59-0.87) and 0.89 (95% CI, 0.71-0.97), respectively. In the subgroup analysis, the CR rate in patients with hysterectomy was 0.98 (95% CI, 0.11-1.0) and in those without hysterectomy was 0.60 (95% CI, 0.30-0.84), and the rate ratio was 0.83 (95% CI, 0.48-1.19). The pooled response rates with and without a history of hysterectomy were not estimated, and the rate ratio was 0.83 (95% CI, 0.54-1.09). CONCLUSION: Imiquimod can be an effective treatment for vaginal intraepithelial neoplasia 2-3.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Inayama Y, Yamanishi Y, Nakatani E, et al. Imiquimod for vaginal intraepithelial neoplasia 2-3: A systematic review and meta-analysis. Gynecol Oncol. 2020. PMID: 33010966. doi:10.1016/j.ygyno.2020.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。